Tisotumab vedotin - Genmab/Seattle Genetics

Drug Profile

Tisotumab vedotin - Genmab/Seattle Genetics

Alternative Names: Humax TF ADC; HuMax-TF; HuMax-TF-ADC; TF-011-MMAE; Tisotumab vedotin

Latest Information Update: 17 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Genmab
  • Class Antineoplastics; Auristatins; Drug conjugates; Immunotoxins; Monoclonal antibodies
  • Mechanism of Action Thromboplastin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Bladder cancer; Cervical cancer; Endometrial cancer; Oesophageal cancer; Ovarian cancer; Prostate cancer; Solid tumours

Most Recent Events

  • 08 Jan 2018 Seattle Genetics plans a phase II trial for Solid tumours (Monotherapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in June 2018 (IV) (NCT03485209)
  • 08 Jan 2018 Seattle Genetics plans a phase II trial for Cervical cancer (Combination therapy, first line therapy)
  • 10 Oct 2017 Genmab plans the phase II registrational GCT1015-04 study for Cervical cancer (Metastatic disease, Second-line or greater therapy, Monotherapy) in the first half of 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top